2.22

2.05% 0.02

Lyra Therapeutics Inc (LYRA)

Overview News Price History Option Chain Financials Discussions Forecast

Lyra Therapeutics Inc stock is traded at $2.22, with a volume of 4,616. It is up +2.05% in the last 24 hours and down -36.94% over the past month. Lyra Therapeutics Inc is a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients. The Company's operations and manages its business as a single operating segment which is the business of developing targeted medicines to address ears, nose, and throat, or ENT diseases. Its initial product candidates, LYR-210 and LYR-220, are bioabsorbable polymeric matrices designed to be administered in a brief, non-invasive, in-office procedure and intended to deliver continuous drug therapy to the sinonasal passages for the treatment of chronic rhinosinusitis, or CRS.

Previous Close:

$2.20

Open:

$2.24

24h Volume:

4,616

Relative Volume:

0.06

Market Cap:

$3.93M

Revenue:

$770.00K

Net Income/Loss:

$-38.84M

P/E Ratio:

-0.1563

EPS:

-14.2049

Net Cash Flow:

$-43.02M

1W Performance:

+12.82%

1M Performance:

-36.94%

6M Performance:

-73.24%

1Y Performance:

-75.90%

1-Day Range:

$2.21

$2.31

1-Week Range:

$1.94

$2.58

52-Week Range:

$1.63

$37.50

Lyra Therapeutics Inc Stock (LYRA) Company Profile

Name

Lyra Therapeutics Inc

Sector

Healthcare (1119)

Industry

Biotechnology (625)

Phone

617-373-4600

Address

480 ARSENAL WAY, WATERTOWN, MA

Employee

Twitter

@LyraTx

Next Earnings Date

2025-03-12

Latest SEC Filings

LYRA's Discussions on Twitter

Compare LYRA with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
LYRA Lyra Therapeutics Inc	2.2116	3.90M	770.00K	-38.84M	-43.02M	-14.20
VRTX Vertex Pharmaceuticals Inc	467.50	118.58B	11.74B	3.68B	3.34B	14.19
REGN Regeneron Pharmaceuticals Inc	753.66	79.40B	14.25B	4.58B	3.88B	41.77
ARGX Argen X Se Adr	831.39	51.18B	3.06B	1.28B	447.35M	19.67
ALNY Alnylam Pharmaceuticals Inc	363.32	48.88B	3.21B	43.57M	221.36M	0.2405
ONC Beone Medicines Ltd Adr	341.01	37.49B	4.98B	69.59M	525.67M	0.5197

Lyra Therapeutics Inc Stock (LYRA) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
May-07-24	Downgrade	BofA Securities	Buy → Underperform
May-07-24	Downgrade	H.C. Wainwright	Buy → Neutral
May-07-24	Downgrade	Jefferies	Buy → Hold
May-06-24	Downgrade	William Blair	Outperform → Mkt Perform
Oct-06-23	Resumed	BTIG Research	Buy
Aug-31-23	Initiated	H.C. Wainwright	Buy
May-24-22	Initiated	Cantor Fitzgerald	Overweight
May-26-20	Initiated	BTIG Research	Buy
May-26-20	Initiated	BofA/Merrill	Buy
May-26-20	Initiated	Jefferies	Buy
May-26-20	Initiated	William Blair	Outperform

View All

Lyra Therapeutics Inc Stock (LYRA) Latest News

Jan 20, 2026

How Lyra Therapeutics Inc. stock reacts to Fed rate cutsFederal Reserve Announcements & Fast Growing Portfolio Trading - bollywoodhelpline.com

Jan 20, 2026

Jan 18, 2026

How cyclical is Lyra Therapeutics Inc.’s revenue streamPortfolio Performance Summary & Accurate Intraday Trading Signals - bollywoodhelpline.com

Jan 18, 2026

Jan 16, 2026

Weekly Buzz: LYRA Slashes Jobs; FDA Okays FBIO's ZYCUBO; BSX To Acquire PEN; BCTX On Watch - RTTNews

Jan 16, 2026

Jan 15, 2026

Aug Spikes: Is Lyra Therapeutics Inc stock a good pick for beginnersJuly 2025 Recap & Consistent Return Strategy Ideas - baoquankhu1.vn

Jan 15, 2026

Bearish Setup: Will Cheniere Energy Inc stock hit new highs in YEARWeekly Loss Report & Safe Entry Point Identification - baoquankhu1.vn

Jan 15, 2026

Jan 14, 2026

Layoff Tracker: Lyra Shutters, EMD Serono Downsizes - BioSpace

Jan 14, 2026

How much upside does Lyra Therapeutics Inc. have2025 Valuation Update & Weekly Sector Rotation Insights - bollywoodhelpline.com

Jan 14, 2026

Jan 13, 2026

Will Lyra Therapeutics Inc be affected by tariffsJuly 2025 Setups & Free AI Powered Buy and Sell Recommendations - baoquankhu1.vn

Jan 13, 2026

EV Market: Will Lyra Therapeutics Inc stock maintain momentum in 2025Analyst Downgrade & Weekly Return Optimization Plans - Bộ Nội Vụ

Jan 13, 2026

Lyra Therapeutics suspends further development of LYR-210 - Yahoo Finance

Jan 13, 2026

Lyra Therapeutics halts development of lead CRS treatment By Investing.com - Investing.com Nigeria

Jan 13, 2026

Jan 12, 2026

Mass. biotech company lays off entire workforce as cash dwindles - nbcboston.com

Jan 12, 2026

Gold Rises Sharply; Lyra Therapeutics Shares Plunge - Benzinga

Jan 12, 2026

12 Health Care Stocks Moving In Monday's Intraday Session - Benzinga

Jan 12, 2026

Watertown biotech suspends drug development and eliminates workforce as cash dwindles - The Business Journals

Jan 12, 2026

LYRA Plunges 55% After Company Halts Lead Program And Begins Strategic Review - Nasdaq

Jan 12, 2026

Why Is Lyra Therapeutics Stock (LYRA) Down Today? - TipRanks

Jan 12, 2026

Lyra Therapeutics plunges after halting development of lead nasal drug - TradingView — Track All Markets

Jan 12, 2026

Lyra Therapeutics Inc terminates CEO Maria Palasis and CFO Jason CavalierSEC filing - marketscreener.com

Jan 12, 2026

Lyra Therapeutics halts development of lead CRS treatment - Investing.com

Jan 12, 2026

Lyra Therapeutics Provides Corporate Update - The Manila Times

Jan 12, 2026

Jan 09, 2026